Albrecht Stenzinger

Albrecht Stenzinger's AcademicInfluence.com Rankings

Albrecht Stenzinger

Computer Science

#9125

World Rank

#9588

Historical Rank

Software Engineering

#241

World Rank

#245

Historical Rank

Computational Linguistics

#2159

World Rank

#2181

Historical Rank

Machine Learning

#3918

World Rank

#3965

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Albrecht Stenzinger Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Albrecht Stenzinger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018) (1327)
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay (2013) (926)
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. (2012) (569)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020) (432)
SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas (2021) (322)
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (231)
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project (2020) (231)
Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach (2012) (220)
BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. (2012) (203)
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. (2020) (200)
The landscape of metastatic progression patterns across major human cancers (2014) (192)
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer (2013) (191)
Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment. (2019) (176)
Integrative genomic and transcriptomic analysis of leiomyosarcoma (2018) (174)
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma (2016) (168)
Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells (2014) (153)
Sarcoma classification by DNA methylation profiling (2021) (147)
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. (2018) (136)
Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions (2019) (134)
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. (2018) (131)
A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications (2018) (129)
Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis (2018) (123)
Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas (2017) (118)
Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role (2014) (118)
Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. (2013) (114)
Precision oncology based on omics data: The NCT Heidelberg experience (2017) (111)
The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). (2011) (110)
Accurate and efficient detection of gene fusions from RNA sequencing data (2021) (109)
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. (2010) (106)
Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway (2014) (104)
Three molecular pathways model colorectal carcinogenesis in Lynch syndrome (2018) (103)
ROS1 expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 cases (2014) (101)
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma (2014) (100)
Correlation of radio- and histomorphological pattern of pulmonary adenocarcinoma (2012) (99)
Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas (2012) (99)
mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. (2011) (95)
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype (2013) (95)
Classical pathology and mutational load of breast cancer – integration of two worlds (2015) (93)
Postoperative Complications Deteriorate Long-Term Outcome in Pancreatic Cancer Patients (2012) (87)
Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment (2011) (86)
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panels (2019) (85)
Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274) – associations with gene expression, mutational load, and survival (2016) (83)
Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm (2014) (79)
Survival of Patients with Oral Cavity Cancer in Germany (2013) (77)
Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. (2015) (75)
Prognostic Impact and Clinicopathological Correlations of the Cribriform Pattern in Pulmonary Adenocarcinoma (2015) (74)
EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancer (2018) (74)
Potential clinical implications of BRAF mutations in histiocytic proliferations (2014) (73)
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. (2021) (71)
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients (2014) (71)
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases (2019) (69)
High‐throughput diagnostic profiling of clinically actionable gene fusions in lung cancer (2016) (68)
Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. (2010) (67)
Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens* (2016) (65)
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma (2016) (65)
Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach (2012) (65)
Optimizing panel-based tumor mutational burden (TMB) measurement. (2019) (65)
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response (2017) (64)
Loss of SOX2 expression induces cell motility via vimentin up‐regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma (2015) (63)
Morphological and molecular breast cancer profiling through explainable machine learning (2021) (62)
Variant classification in precision oncology (2019) (59)
Who Is at Risk for Diagnostic Discrepancies? Comparison of Pre- and Postmortal Diagnoses in 1800 Patients of 3 Medical Decades in East and West Berlin (2012) (59)
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification (2016) (59)
Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast—implications for tumor biology and pathological diagnosis (2015) (58)
The landscape of chromothripsis across adult cancer types (2020) (58)
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences (2014) (58)
Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma (2018) (57)
Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts. (2019) (57)
Automated sample preparation with SP3 for low‐input clinical proteomics (2020) (56)
Harmonization and Standardization of Panel-Based Tumor Mutational Burden (TMB) Measurement: Real-World Results and Recommendations of the QuIP Study. (2020) (55)
Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer (2015) (55)
Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification (2012) (54)
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma (2019) (53)
The combinatorial complexity of cancer precision medicine (2014) (52)
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden (2018) (51)
Mutations in POLE and survival of colorectal cancer patients – link to disease stage and treatment (2014) (51)
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy (2016) (50)
Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma (2019) (50)
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma (2017) (49)
Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project. (2021) (49)
Automated sample preparation with SP3 for low-input clinical proteomics (2019) (49)
MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. (2017) (48)
Down‐regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer (2012) (47)
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma (2013) (47)
Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays (2020) (46)
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. (2016) (46)
Optimizing panel-based tumor mutational burden (TMB) measurement. (2019) (44)
Cancer beyond organ and tissue specificity: Next‐generation‐sequencing gene mutation data reveal complex genetic similarities across major cancers (2014) (43)
Molecular driver alterations and their clinical relevance in cancer of unknown primary site (2016) (42)
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes (2020) (42)
CognitionMaster: an object-based image analysis framework (2013) (42)
Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. (2020) (41)
Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. (2016) (41)
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer (2020) (41)
Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology (2016) (39)
Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy. (2020) (39)
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). (2020) (38)
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors (2020) (37)
ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. (2015) (37)
KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma (2014) (37)
EWSR1/FUS-CREB Fusions Define a Distinctive Malignant Epithelioid Neoplasm with Predilection for Mesothelial-Lined Cavities (2020) (37)
Evaluation of a hybrid capture-based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes. (2020) (35)
Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer (2015) (35)
Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix (2018) (35)
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples (2019) (35)
High nuclear poly‐(ADP‐ribose)‐polymerase expression is prognostic of improved survival in pancreatic cancer (2012) (35)
Copy number changes of clinically actionable genes in melanoma, non‐small cell lung cancer and colorectal cancer—A survey across 822 routine diagnostic cases (2016) (35)
The BRCA2 mutation status shapes the immune phenotype of prostate cancer (2019) (35)
Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitors (2017) (34)
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival (2019) (34)
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types (2017) (33)
Allelic ratio of KRAS mutations in pancreatic cancer. (2015) (33)
Mutations in BRCA2 and taxane resistance in prostate cancer (2017) (33)
Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma (2016) (32)
Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities (2020) (32)
Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma (2020) (32)
Establishment of a patient-derived orthotopic osteosarcoma mouse model (2015) (31)
Artificial Intelligence and Pathology: from Principles to Practice and Future Applications in Histomorphology and Molecular Profiling. (2021) (31)
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol (2017) (31)
High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. (2012) (30)
Defining molecular risk in ALK+ NSCLC (2019) (30)
Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66) (2013) (29)
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). (2021) (28)
Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study (2018) (28)
PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3β and PTP1B in situ. (2011) (28)
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial (2018) (28)
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence. (2020) (28)
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model (2012) (28)
Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance (2019) (27)
EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial (2017) (27)
NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial (2016) (27)
RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours (2019) (27)
The novel protein PTPIP51 exhibits tissue- and cell-specific expression (2004) (27)
The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. (2019) (27)
Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. (2019) (26)
Towards computational fluorescence microscopy: Machine learning-based integrated prediction of morphological and molecular tumor profiles (2018) (26)
Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer (2013) (25)
EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC. (2018) (25)
Cell and molecular biology of the novel protein tyrosine-phosphatase-interacting protein 51. (2009) (25)
The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability (2016) (25)
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma (2021) (25)
Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination (2022) (25)
Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate (2018) (25)
In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients (2019) (25)
Endometrial stromal sarcomas with BCOR‐rearrangement harbor MDM2 amplifications (2020) (25)
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA (2020) (25)
Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study (2021) (24)
Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. (2017) (23)
Mutations in genes encoding PI3K‐AKT and MAPK signaling define anogenital papillary hidradenoma (2016) (22)
Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information (2018) (22)
NTRK testing: First results of the QuiP‐EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA‐based NGS assays (2020) (22)
Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas (2017) (21)
Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies (2016) (21)
Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment (2016) (21)
cancerclass: An R Package for Development and Validation of Diagnostic Tests from High-Dimensional Molecular Data (2014) (21)
Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. (2019) (21)
Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer (2017) (21)
Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. (2018) (21)
Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K–AKT pathway (2017) (21)
GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma (2015) (21)
Follicle‐stimulating hormone receptor expression in soft tissue sarcomas (2013) (20)
Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance (2017) (20)
Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility (2018) (20)
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. (2020) (20)
Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice (2017) (20)
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). (2022) (19)
Expression profile of PTPIP51 in mouse brain (2009) (19)
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer (2021) (19)
Quantitative analysis of diagnostic guidelines for HER2-status assessment. (2012) (19)
Epidermal Growth Factor-, Transforming Growth Factor-β-, Retinoic Acid- and 1,25-Dihydroxyvitamin D3-Regulated Expression of the Novel Protein PTPIP51 in Keratinocytes (2007) (19)
Health Care Infrastructure for Financially Sustainable Clinical Genomics. (2016) (19)
Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment (2020) (19)
Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas (2018) (18)
Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples (2021) (18)
Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome (2019) (18)
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer (2021) (18)
Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications (2022) (17)
Novel GATA6-FOXO1 Fusions in a Subset of Epithelioid Hemangioma (2020) (17)
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (17)
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy (2019) (17)
Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. (2020) (17)
Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer. (2012) (17)
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma (2021) (17)
Genetic changes of non-small cell lung cancer under neoadjuvant therapy (2016) (17)
Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study (2018) (17)
Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations. (2021) (16)
The novel protein PTPIP51 is expressed in human keratinocyte carcinomas and their surrounding stroma (2008) (16)
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing. (2020) (16)
Decreased RECK and Increased EMMPRIN Expression in Urothelial Carcinoma of the Bladder Are Associated with Tumor Aggressiveness (2011) (16)
Nivolumab maintenance after salvage autologous stem cell transplantation results in long‐term remission in multiple relapsed primary CNS lymphoma (2018) (16)
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer (2021) (16)
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy (2015) (16)
The different immune profiles of normal colonic mucosa in cancer-free Lynch syndrome carriers and Lynch syndrome colorectal cancer patients (2021) (15)
DNA Index as a Strong Prognostic Factor in Patients With Adenocarcinoma of the Pancreatic Head: Results of a 5-Year Prospective Study (2013) (15)
Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model (2013) (15)
Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study (2014) (15)
Individualized medicine and demographic change as determining workload factors in pathology: quo vadis? (2015) (15)
Blood BRAFV 600 E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis (2012) (15)
Qualitative Comparison Between Carrier-based and Classical Tissue Microarrays (2017) (15)
Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer (2014) (15)
Basket Trials: Just the End of the First Quarter. (2015) (15)
Digital PCR After MALDI–Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma (2018) (15)
Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology (2017) (15)
p53 partial loss-of-function mutations sensitize to chemotherapy (2021) (14)
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma (2016) (14)
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. (2022) (14)
Targeting irradiation‐induced mitogen‐activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer (2016) (14)
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer (2019) (14)
Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial (2020) (14)
Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains (2019) (14)
Comparison of Prostate MRI Lesion Segmentation Agreement Between Multiple Radiologists and a Fully Automatic Deep Learning System (2020) (14)
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines (2017) (14)
Incidental postmortem diagnosis of DIPNECH in a patient with previously unexplained 'asthma bronchiale'. (2010) (13)
The DNA index is a strong predictive marker in intrahepatic cholangiocarcinoma: the results of a five-year prospective study (2014) (13)
Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. (2018) (13)
Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux. (2017) (13)
Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer (2019) (13)
Fully Automatic Deep Learning in Bi-institutional Prostate Magnetic Resonance Imaging: Effects of Cohort Size and Heterogeneity. (2021) (13)
KRAS/GNAS‐testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound‐guided workup of suspected mucinous neoplasms of the pancreas (2021) (13)
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab (2015) (12)
Revisiting the Role of p53 in Prostate Cancer (2021) (12)
Recurrent YAP1-TFE3 Gene Fusions in Clear Cell Stromal Tumor of the Lung (2021) (12)
Community-driven development of a modified progression-free survival ratio for precision oncology (2019) (12)
Molekulare Diagnostik in der Pathologie (2013) (12)
Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing (2019) (12)
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis (2021) (12)
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies (2021) (12)
Noncompaction myocardium in association with type Ib glycogen storage disease. (2012) (12)
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer (2021) (12)
Genomics of Immunotherapy-Associated Hyperprogressors—Letter (2017) (11)
Genomic features of renal cell carcinoma with venous tumor thrombus (2018) (11)
Next-generation sequencing: hype and hope for development of personalized radiation therapy? (2015) (11)
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma (2021) (11)
Prolyl Hydroxylase Domain 2 Protein Is a Strong Prognostic Marker in Human Gastric Cancer (2012) (11)
Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes (2020) (11)
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary (2020) (11)
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel. (2020) (11)
Neue morphologische und molekulare Aspekte des Lungenkarzinoms (2013) (11)
Homologous Recombination Deficiency: Concepts, Definitions, and Assays (2022) (11)
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer (2021) (11)
Protein Tyrosine Phosphatase Interacting Protein 51 (PTPIP51) mRNA Expression and Localization and Its In Vitro Interacting Partner Protein Tyrosine Phosphatase 1B (PTP1B) in Human Placenta of the First, Second, and Third Trimester (2009) (10)
Expression of PTPIP51 during mouse eye development (2008) (10)
Improvement of PI-RADS-dependent prostate cancer classification by quantitative image assessment using radiomics or mean ADC. (2021) (10)
Unmasked: when a clinically malignant disease turns out infectious. A rare case of tularemia. (2013) (10)
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer (2020) (10)
PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma (2009) (9)
Homologous recombination repair deficiency (HRD): From biology to clinical exploitation (2021) (9)
PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor (2015) (9)
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. (2017) (9)
Semiconductor-based sequencing of formalin-fixed, paraffin-embedded colorectal cancer samples. (2015) (9)
Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature (2021) (9)
Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR‐mutated lung cancer (2018) (9)
Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC (2019) (9)
Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. (2020) (9)
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV (2021) (9)
Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS (2019) (9)
Histological tumor typing in the age of molecular profiling. (2015) (9)
Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy (2020) (8)
Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine (2021) (8)
Ataxia-telangiectasia–Mutated Protein Kinase Levels Stratify Patients With Pancreatic Adenocarcinoma Into Prognostic Subgroups With Loss Being a Strong Indicator of Poor Survival (2015) (8)
Precision oncology: a clinical and patient perspective. (2021) (8)
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types (2021) (8)
Genetic Profiling of Cancers of the Digestive System: Biological Insights and Clinical Implications (2017) (8)
Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report (2016) (8)
Measured Multipoint Ultra-High b-Value Diffusion MRI in the Assessment of MRI-Detected Prostate Lesions (2020) (8)
Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder (2021) (8)
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. (2021) (8)
Integrating proteomics into precision oncology (2020) (8)
Would Virchow be a systems biologist? A discourse on the philosophy of science with implications for pathological research (2010) (8)
Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma (2020) (7)
Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing (2020) (7)
Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. (2019) (7)
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future (2020) (7)
Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma (2017) (7)
Knowledge bases and software support for variant interpretation in precision oncology (2021) (7)
Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. (2018) (7)
Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. (2021) (7)
Immuno‐oncology gene expression profiling of formalin‐fixed and paraffin‐embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing (2020) (7)
Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes (2019) (7)
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD) (2022) (7)
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity (2022) (7)
10PComparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls (2017) (7)
Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary. (2018) (7)
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer (2021) (6)
Pathologie der malignen Kopf-Hals-Tumoren (2014) (6)
Einfluss der neuen In-vitro-Diagnostik-Regulation (IVDR) der Europäischen Union auf die Pathologie. Was ist wichtig? (2020) (6)
Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen (2020) (6)
TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib (2022) (6)
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field. (2021) (6)
Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies: Looking at the Soil Before Planting the Seed (2016) (6)
Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management (2021) (6)
[Novel morphological and molecular aspects of lung cancer]. (2013) (6)
[Molecular diagnostics of non-small cell lung cancer: New markers and technologies]. (2015) (6)
Molecular dissection of large cell carcinomas of the lung with null immunophenotype. (2018) (6)
Expression of the novel protein PTPIP51 in rat liver: an immunohistochemical study (2007) (6)
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. (2017) (6)
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma * (2021) (6)
Die Rolle der Pathologie in der Diagnostik des CUP-Syndroms (2014) (6)
Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. (2021) (6)
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. (2022) (5)
PARP inhibition in BRCA2-mutated prostate cancer. (2016) (5)
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives (2020) (5)
Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations. (2018) (5)
Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma (2020) (5)
MA14.01 Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non–Small Cell Lung Cancer (2021) (5)
Laboratory-Developed Tests in the New European Union 2017/746 Regulation: Opportunities and Risks. (2021) (5)
RREB1-MKL2 fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site? (2021) (5)
Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma (2014) (5)
Interference of amphiregulin and EGFRvIII expression with outcome of patients with squamous cell carcinoma of the head and neck (SCCHN) receiving cetuximab-docetaxel treatment. (2011) (5)
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report (2021) (5)
Visceral leishmaniasis in a patient with AIDS: early pathological diagnosis using conventional histology, PCR and electron microscopy is the key for adequate treatment (2012) (5)
Tumor mutational burden (TMB) standardization initiative: Establishing a consistent methodology for TMB measurement in clinical samples. (2018) (5)
Targeting DNA Damage Repair Mechanisms in Pancreas Cancer (2021) (5)
Distinct immune evasion in APOBEC‐enriched, HPV‐negative HNSCC (2020) (5)
Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival (2021) (5)
Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing (2021) (5)
Advisory opinion of the AWMF Ad hoc Commission In-vitro Diagnostic Medical Devices regarding in-vitro diagnostic medical devices manufactured and used only within health institutions established in the Union according to Regulation (EU) 2017/746 (IVDR) (2021) (5)
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma (2021) (5)
Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression (2021) (4)
Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1 (2019) (4)
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. (2022) (4)
Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer (2021) (4)
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types (2022) (4)
PARP inhibition in BRCA2-mutated prostate cancer. (2017) (4)
LBA58 ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial (2020) (4)
[Impact of the novel in vitro diagnostic regulation (IVDR) of the European Union on pathology laboratories. What's important?] (2020) (4)
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial (2020) (4)
Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma (2021) (4)
Primary neoplasms of the parapharyngeal space: diagnostic and therapeutic pearls and pitfalls (2021) (4)
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). (2022) (4)
Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model (2017) (4)
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing (2022) (4)
Comparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer. (2021) (4)
Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations (2021) (4)
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial (2021) (4)
Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms (2015) (4)
Prostatic metastasis from intrahepatic cholangiocarcinoma (2018) (3)
Adaptive Immunity and Pathogenesis of Diabetes: Insights Provided by the α4–Integrin Deficient NOD Mouse (2020) (3)
Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC (2019) (3)
Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders (2018) (3)
Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets (2021) (3)
FGFR2 Inhibition in Cholangiocarcinoma. (2022) (3)
Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib (2022) (3)
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. (2021) (3)
Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium (2019) (3)
Harmonization and standardization of panel-based tumour mutational burden (TMB) measurement: Real-world results and recommendations of the QuIP study (2019) (3)
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice (2022) (3)
SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report (2021) (3)
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors (2022) (3)
Type, Density, and Location of Immune Cells within Cholangiocarcinomas Predict Clinical Outcome (2012) (3)
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy (2017) (2)
Integrated Clinico-Molecular Characterization Identifies RAS Activation and CDKN2A Deletion As Independent Adverse Prognostic Factors in Cancer of Unknown Primary (2019) (2)
Germline SDHB‐inactivating mutation in gastric spindle cell sarcoma (2020) (2)
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting (2022) (2)
Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data (2018) (2)
Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations (2022) (2)
[Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group]. (2019) (2)
Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA‐binding protein 3 in non‐small‐cell lung cancer (2020) (2)
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report (2022) (2)
572P High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer (2022) (2)
Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. (2020) (2)
Pseudoprospective Paraclinical Interaction of Radiology Residents With a Deep Learning System for Prostate Cancer Detection (2022) (2)
Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis (2022) (2)
KIT mutations in primary mediastinal B-cell lymphoma (2014) (2)
A phase II clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. (2023) (2)
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary (2022) (2)
Abstract 1624: SIRT1 overexpression in pancreatic adenocarcinomas correlates with shortened patient survival and small molecule inhibition as well as target knockdown of SIRT1 induces growth arrest and apoptosis in pancreatic cancer cells (2011) (2)
Genomic profiling using targeted ultra-deep next-generation sequencing for prediction of treatment outcome after concurrent chemoradiation: Results from the German ARO-0401 trial. (2014) (2)
Acute expression of human APOBEC3B in mice causes lethality associated with RNA editing (2022) (2)
Intrinsic subtypes and risk scores in ER+/HER2-Breast Cancer: a comparison of Prosigna and OncotypeDX risk categories with Ki67 (2017) (2)
PARP inhibition in prostate cancer (2020) (2)
153P Real-world study of NSCLC with EGFR exon 20 insertions (2021) (2)
Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report (2022) (2)
Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis (2022) (2)
Abstract 919: Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium (2019) (2)
Mutations of cancer-related genes in benign tumors: the example of hidradenoma papilliferum. (2017) (2)
36P Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC) (2022) (1)
Frequency and clinical impact of atypical EGFR mutations in lung adenocarcinoma (2019) (1)
306 Subtype-specific Models of Pancreatic Ductal Adenocarcinoma Reveal Signaling Pathways That Can Be Exploited Therapeutically (2012) (1)
Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer (2018) (1)
Abstract 5010: Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer (2016) (1)
Detection of clinically relevant gene fusions in plasma samples of lung cancer patients in routine molecular diagnostics. (2018) (1)
Abstract P3-07-03:PIK3CAmutations predict resistance to trastuzumab/pertuzumab andnab-paclitaxel in primary HER2-positive breast cancer – Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study (2016) (1)
Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway (2021) (1)
Cancer of Unknown Primary: The Pathologist’s Approach (2016) (1)
Allelic ratio of KRAS mutations in pancreatic ductal adenocarcinoma. (2015) (1)
Determination of tumor mutational burden using FFPE material: Content and performance comparison of different gene panels. (2018) (1)
[Student Academy of the German Society of Pathology]. (2013) (1)
[Variant interpretation in molecular pathology and oncology : An introduction]. (2021) (1)
Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis: results from the Onconetwork Immuno-Oncology Consortium. (2021) (1)
Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms. (2018) (1)
De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer (2021) (1)
[Quality assurance in diagnostic in situ hybridization-experience of QuIP]. (2020) (1)
SARS-CoV-2 infects cells of the human exocrine and endocrine pancreas and interferes with beta-cell function (2020) (1)
Absence Of BRAF and KRAS Hotspot Mutations In Primary Mediastinal and Other Diffuse Large B-Cell Lymphoma (2013) (1)
Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial (2019) (1)
Profiling of Oncogenic Signaling in Multiple Myeloma — Association with Biology, Disease Progression and Prognosis (2018) (1)
P75.04 Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC (2021) (1)
Abstract 3128: mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumors (2010) (1)
758P Concordance between multiple HRD assays is substantial in high-grade ovarian cancer (2021) (1)
Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder (2021) (1)
Abstract 468: Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies: Results from the MASTER trial of the German Cancer Consortium (2019) (1)
[Spindle and giant cell type undifferentiated carcinoma of the distal bile duct: a case report]. (2019) (1)
Struktur und Inhalt der EU-IVDR (2022) (1)
Undifferenziertes Karzinom des distalen Gallengangs vom Spindel- und Riesenzelltyp: Ein Fallbericht (2019) (1)
Resistance against PSMA-targeting alpha-radiation therapy coincides with mutations in DNA-repair associated genes (2019) (1)
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma (2013) (1)
Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma (2022) (1)
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model (2012) (1)
Expanding the molecular spectrum of gene fusions in endometrial stromal sarcoma: Novel subunits of the chromatin remodeling complexes PRC2 and NuA4/TIP60 as alternative fusion partners (2022) (1)
Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression (2022) (1)
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients (2022) (1)
Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards (2022) (1)
MCL1 as putative target in pancreatoblastoma (2022) (1)
Impact of Surgeon’s Experience in Rigid versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores (2022) (1)
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy (2022) (1)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
139P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy: Real-world data from two certified lung cancer centers in Germany (2021) (0)
8P Pre-treatment blood gene expression changes associated with durable clinical benefit in metastatic non-small cell lung cancer with high PD-L1 expression receiving first-line pembrolizumab (2021) (0)
Abstract P2-03-09: Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls (2017) (0)
Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course". (2016) (0)
Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study (Preprint) (2020) (0)
118P The clinical utility of advanced lung inflammation index (ALI) for immunotherapy guidance in non-small cell lung cancer (2021) (0)
Abstract 4125: Precise and reproducible measurement of tumor mutational burden using panel sequencing: the role of panel size and of mutation types (2019) (0)
Abstract 3709: Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types (2017) (0)
P3.02-032 Spatial Heterogeneity of EGFR and KRAS Variant Allele Frequencies Correlates with Histological Patterns of Lung Adenocarcinomas (2017) (0)
Durvalumab in frail and elder patients with stage four NSCLC: Study protocol of the randomized phase II DURATION trial (2019) (0)
50 Influence of microRNA expression profiles on the efficacy of radiochemotherapy in locally advanced head and neck squamous cell carcinoma (2015) (0)
22P Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma (2018) (0)
Abstract 3735: Detection of microsatellite instable colorectal cancers from routine NGS panel sequencing data (2017) (0)
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]. (2021) (0)
Non-Small Cell Lung Cancer-From rational histological algorithms to comprehensive molecular pathological testing (2017) (0)
Mutational Similarities Across Cancers: Implications for Research, Diagnostics, and Personalized Therapy Design (2015) (0)
Abstract 797: Targeted next generation sequencing of FFPE lung cancer tissue. (2013) (0)
Deleted in Malignant Brain Tumors 1 (DMBT1) is differentially expressed in cholangiocarcinogenesis and shows influence on patient survival (2014) (0)
[Congratulations on your birthday, dear Mr. Dietel!]. (2013) (0)
1739P Survival outcomes in patients with sarcomatoid pleural mesothelioma: A retrospective analysis from the last two decades (2021) (0)
[The molecular pathological breviary: allele frequencies in NGS analysis]. (2021) (0)
Abstract 820: Genomics based personalized oncology of cancer of unknown primary (2020) (0)
Abstract 1571: Inter- and intra- tumorheterogeneity of the microenvironment in pulmonary adenocarcinoma (2020) (0)
TP53 status conversion defines an unfavourable patient subset with inferior overall survival in ALK+ lung adenocarcinoma (2019) (0)
Abstract 4101: Spatial heterogeneity of tumor mutational burden (TMB) counts in pulmonary adenocarcinoma: Separating biological effects from technical artifacts (2019) (0)
MP77-20 PREDICTION OF SIGNIFICANT PROSTATE CANCER IN BIOPSY-NAÏVE MEN: EXTERNAL VALIDATION OF A NOVEL RISK MODEL COMBINING MRI AND CLINICAL PARAMETERS (2018) (0)
Abstract LB-287: Identification of patients at risk for tumor predisposition syndromes based on the evaluation of sporadic cancer exome sequencing data: experiences from the NCT/DKTK MASTER program (2017) (0)
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma (2019) (0)
The value of PSA density in PI-RADS 3 lesions on multiparametric MRI - a strategy to avoid unnecessary prostate biopsies (2020) (0)
Abstract 2391: HPV status predicts therapy response in patients with locally advanced HNSCC receiving cetuximab-based radioimmunotherapy. (2013) (0)
MP20-07 PREOPERATIVE MRI AND CLINICAL PARAMETERS FOR ACCURATE PREDICTION OF CONTINENCE RECOVERY FOLLOWING RADICAL PROSTATECTOMY – MEMBRANOUS URETHRAL LENGTH ON MRI OUTPERFORMS PREDICTIVE MODELS (2018) (0)
MiRNAs involved in development of intraepithelial precursor lesions and progression to cholangiocarcinoma (2019) (0)
Abstract 1891: Mutations in polymerase ε as key molecular alteration of the novel ultramutator phenotype do not define a clinically distinct entity of colorectal cancer (2014) (0)
ADJUVANT CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER IN ELDERLY PATIENTS: REAL-WORLD DATA ON TOLERANCE AND SAFETY (2019) (0)
Cholangiocarcinogenesis is a developmental process driven by distinct sequential alterations of the cellular transcriptome (2019) (0)
COGNITION – Präzisionsmedizin bei Brustkrebs im Frühstadium (2020) (0)
Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie (2021) (0)
Herzlichen Glückwunsch zum Geburtstag, lieber Herr Dietel! (2013) (0)
Zentralisierte Molekulare Tumordiagnostik durch kommerzielle Anbieter (2018) (0)
Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading (2022) (0)
RSPO2 gene rearrangement – a new cancer driver in the liver (2019) (0)
Genexpressionanalyse von Mammakarzinomen mittels Prosigna® Assay (NanoString Technologies, Seattle WA) im klinischen Alltag und Einfluss auf die Entscheidung des Onkologen hinsichtlich Systemtherapie (2017) (0)
Fusions in Wild-Type Pancreatic Cancer. (2018) (0)
Molekulare Prädiktoren zur Abschätzung des Therapieansprechens auf eine neoadjuvante Systemtherapie von Patientinnen mit frühem Her2-positivem Mammakarzinom (2019) (0)
Binäre schichtweise Tumorklassifikation auf Prostata-MRTs mit Hilfe eines vortrainierten ResNet18 (2021) (0)
Das molekularpathologische Brevier: Was heißt: „WGS, WES, Transkriptom, RNAseq“? (2022) (0)
Prädiktive Biomarker in der immunonkologischen Therapie gastrointestinaler Tumoren: derzeitiger Standard und zukünftige Perspektiven (2021) (0)
Praktische Durchführung der ärztlichen Leichenschau – Aufgabenkomplexe (2019) (0)
Das molekularpathologische Brevier: Lesetiefe und Coverage in der NGS-Analytik (2021) (0)
Dauerhaftes Ansprechen auf Olaparib und endokrine Therapie bei einer Patientin mit metastasiertem luminalem Mammakarzinom und gBRCA-Mutation (2020) (0)
Erratum (2019) (0)
Status der Verfügbarkeit und Anwendung von „next generation sequencing“ (NGS) beim Harnblasenkarzinom – eine Umfrage in der Arbeitsgemeinschaft Uropathologie (2019) (0)
Varianteninterpretation in der molekularen Pathologie und Onkologie (2021) (0)
MP56-07 THE VALUE OF PSA DENSITY IN PI-RADS 3 LESIONS ON MULTIPARAMETRIC MRI - A STRATEGY TO AVOID UNNECESSARY PROSTATE BIOPSIES (2020) (0)
Von der Paneldiagnostik zu umfassenden genomischen Analysen (2019) (0)
Genomanalyse maligner Tumoren (2019) (0)
Erratum zu: Gene und Pathways: FGFR2-Translokationen und Fusionsanalytik (2022) (0)
Abstract 3093: Quantifying the confounders of panel-based tumor mutational burden (TMB) measurement (2020) (0)
Das molekularpathologische Brevier: Allelfrequenzen in der NGS-Analytik (2021) (0)
COGNITION - Präzisionsmedizin bei Brustkrebs im Frühstadium (2020) (0)
Qualitätssicherung in der diagnostischen In-situ-Hybridisierung – Erfahrungen der QuIP (2020) (0)
Dauerhaftes Ansprechen auf Olaparib und endokrine Therapie bei einer Patientin mit metastasiertem luminalem Mammakarzinom und gBRCA-Mutation (2020) (0)
Mitteilungen der Deutschen Gesellschaft für Pathologie (2012) (0)
Preoperative magnetic resonance imaging and clinical parameters for accurate prediction of continence recovery following radical prostatectomy – membranous urethral length measurement on MRI outperform predictive models (2018) (0)
Karzinome mit unklarer Primärlokalisation – CheCUP‑Studie (2019) (0)
Erratum (2021) (0)
P3.02b-109 Molecular Profiling of EGFR-Positive NSCLC with Secondary T790M Resistance Mutation and Tertiary Transformation into Small-Cell Lung Cancer: Topic: EGFR RES (2017) (0)
Obduktionen (2019) (0)
Gene und Pathways: FGFR2‑Translokationen und Fusionsanalytik (2022) (0)
The landscape of chromothripsis across adult cancer types (2020) (0)
Abstract 821: Comprehensive genomic analysis of rare cancers: Results of the MASTER precision oncology trial of the German Cancer Consortium (2020) (0)
Clinical and molecular profile of de novo vs. secondary EGFR mutated metastatic non-small-cell lung cancer (2020) (0)
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab (2015) (0)
Partial Postponement of the Application of the In Vitro Diagnostic Medical Devices Regulation in the European Union. (2022) (0)
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study. (2022) (0)
Genomic features of renal cell carcinoma with venous tumor thrombus (2018) (0)
Abstract 630: Detection of copy number variations in breast cancer using targeted sequencing without normal tissue controls (2015) (0)
[The biomarker PIK3CA in tumor pathology]. (2023) (0)
Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling. (2023) (0)
Stellenwert der PAM50-Subklassifikation und des PAM50-Proliferationsscore an der Stanzbiopsie zur Prädiktion der pathologischen Komplettremission nach neoadjuvanter Chemotherapie (2018) (0)
Unmasked (2013) (0)
Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis (2023) (0)
1021P DURATION - a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints (2022) (0)
Methylome screen identifies epigenetically deregulated microRNAs in cholangiocarcinoma (2015) (0)
Community-driven development of a modified progression-free survival ratio for precision oncology trials (2019) (0)
738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial (2022) (0)
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy (2015) (0)
Label-Free Enrichment and Molecular Characterization of Viable 1 Circulating Tumor Cells from Diagnostic Leukapheresis Products . 2 3 Running head : CTCs from DLA for culture and molecular analysis . 4 5 (2019) (0)
Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL (2020) (0)
Real-world data for precision cancer medicine - a European perspective. (2023) (0)
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial (2021) (0)
65P Blood cytokine changes in patients with advanced NSCLC receiving immunotherapy (2022) (0)
Abstract 2607: Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by comprehensive mRNA expression analysis (2023) (0)
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas. (2023) (0)
Corrigendum to 'Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux' [The International Journal of Antimicrobial Agents 50/1 (2017) 55-62]. (2018) (0)
Integrative genomic and transcriptomic analysis of leiomyosarcoma (2018) (0)
54P Determining the utilization and clinical impact of platinum-etoposide for treatment of small cell lung cancer in the routine setting (2021) (0)
Influence of microRNA profiles and immune signatures on the efficacy of radiochemotherapy in locally advanced head and neck squamous cell carcinoma (2016) (0)
Mutations in BRCA2 and taxane resistance in prostate cancer (2017) (0)
Structure and content of the EU-IVDR (2023) (0)
P1.01-58 Comprehensive Serial Biomaterial Acquisition in Advanced NSCLC: Feasibility, Challenges and Perspectives (2019) (0)
First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma (2023) (0)
Current status and implications for pathology (2023) (0)
Abstract A69: A novel mechanism mediates drug resistance in the exocrine-like pancreatic ductal adenocarcinoma (PDAC) subtype (2015) (0)
The Novel Protein PTPIP51 is Upregulated in Rat Liver under Methotrexate Treatment (2005) (0)
Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations (2022) (0)
[Centralized molecular tumor diagnostics by commercial providers : Consequences for patients, patient care, and research]. (2018) (0)
Integrated genotype-phenotype analysis of Familial adenomatous polyposis-associated hepatocellular adenomas (2023) (0)
EP08.01-031 Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response (2022) (0)
Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance (2020) (0)
Next-generation sequencing: hype and hope for development of personalized radiation therapy? (2015) (0)
20. A unified framework for gene fusion representation (2022) (0)
A "two-in-one hit" model of shortcut carcinogenesis in MLH1 Lynch syndrome carriers. (2023) (0)
28P EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2021) (0)
Abstract B77: CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma (2016) (0)
1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry (2020) (0)
Knowledge bases and software support for variant interpretation in precision oncology (2021) (0)
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model (2023) (0)
Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations (2021) (0)
Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data (2018) (0)
Clinical predoctors of immune checkpoint inhibitor efficacy in non-small cell lung cancer (2019) (0)
A framework for risk stratification in EGFR+ lung adenocarcinoma treated with tyrosine kinase inhibitors (2019) (0)
Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non-small Cell Lung Cancer. (2023) (0)
Abstract 1686: Comprehensive genomic and transcriptomic profiling of gastrointestinal stromal tumors (2019) (0)
Abstract 810: HRD is inversely correlated with MSI and identifies immunologically cold tumors in most cancer types (2022) (0)
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types (2017) (0)
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol (2017) (0)
Abstract 926: Genomics-based personalized oncology of advanced thymic epithelial tumors (2023) (0)
Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer. (2023) (0)
Prostatic metastasis from Intrahepatic Cholangiocarcinoma. (2018) (0)
Gene expression-based prediction of pazopanib efficacy in sarcoma. (2022) (0)
Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples (2021) (0)
Establishment of a patient-derived orthotopic osteosarcoma mouse model (2015) (0)
17. Multi-consortia initiative to standardize the representation and curation of oncogenic fusions (2022) (0)
Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations (2022) (0)
67P Blood cell gene expression and clinical characteristics in advanced non-small cell lung cancer with immune-related adverse events (2023) (0)
Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage. (2019) (0)
DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy. (2023) (0)
EML4-ALK fusion variant V3 confers early treatment failure with first and second generation ALK TKI (2018) (0)
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator. (2023) (0)
Comparison of the clinical interpretation of high-dimensional molecular data by two molecular tumor boards. (2020) (0)
Head-to-Head Comparison of S-100 and SOX 10 in the Diagnosis of Melanoma (2021) (0)
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations. (2023) (0)
Das molekularpathologische Brevier: was heißt: „hybrid capture“,„anchored multiplex PCR“ und amplikonbasiert? (2022) (0)
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2022) (0)
Gö-VIP-03: Prof. Dr. Holger Bastians Abteilung Molekulare Onkologie, UMG Originalpublikation: “Increased microtubule assembly rates influence chromosomal instability in colorectal cancer.” In: Nature Cell Biology. in press (DOI: 10.1038/ncb2994). Autoren: (2014) (0)
Abstract 3167: CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer (2016) (0)
[The molecular pathology breviary: What do "WGS, WES, transcriptome, RNAseq" mean?] (2022) (0)
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. (2023) (0)
[Structure and content of the EU-IVDR : Current status and implications for pathology]. (2022) (0)
Global alterations of DNA methylation patterns in cholangiocarcinoma target cancer relevant pathways including Wnt/β-catenin signaling (2013) (0)
Abstract 1063: A clear cell renal cancer metastasis model identifies novel mediators of tumor aggressiveness and predictors of patient survival (2018) (0)
IMPACT OF DEEP TARGETED NEXT GENERATION SEQUENCING ON THE WORK-UP OF PATIENTS WITH PANCREAS CYSTS OR DILATED DUCT - A PROSPECTIVE STUDY WITH EUS-GUIDED FNA (2020) (0)
[The molecular pathology breviary: read depth and coverage in NGS analysis]. (2021) (0)
P1.04-13 Delineating Spatial Heterogeneity of Tumor Mutational Burden (TMB) Counts in Pulmonary Adenocarcinoma (2019) (0)
[From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?] (2019) (0)
Tumor Mutational Burden Standardization Initiative: Establish a Consistent Methodology for TMB Measurement in Clinical Samples: OA05 (2018) (0)
An umbrella concept for patients with advanced intrahepatic cholangiocarcinoma (2020) (0)
Abstract IA22: CYP3A5 mediates resistance to small molecule inhibitors in a subtype of pancreatic ductal adenocarcinoma (2016) (0)
Abstract LB-B08: Identification and characterization of an unusual BRAF fusion oncoprotein with retained autoinhibitory domains (2019) (0)
RAS activation and CDKN2A deletion to predict prognosis in cancer of unknown primary. (2019) (0)
Abstract A21: Longitudinal analysis of cell-free DNA for therapy monitoring of ALK-positive non-small cell lung cancer (2020) (0)
Contribution of immunohistochemical (IHC) markers to the diagnosis of pulmonary carcinoids (2011) (0)
Genomisch-histologische Analyse eines „cancer of unknown primary“ (2017) (0)
TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC. (2018) (0)
PD-L1 as urine biomarker in urological malignancies (2023) (0)
Abstract 449: A standard operating procedure for the curation of gene fusions (2021) (0)
Abstract 2652: Pan-cancer analysis of programmed death-ligand 1 (PD-L1) amplifications (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Albrecht Stenzinger?

Albrecht Stenzinger is affiliated with the following schools:

Kiel University
Technical University of Munich
Massachusetts General Hospital
Harvard University
Heidelberg University

Albrecht Stenzinger's Academic­Influence.com Rankings

Why Is Albrecht Stenzinger Influential?

Albrecht Stenzinger's Published Works

Published Works

What Schools Are Affiliated With Albrecht Stenzinger?

Albrecht Stenzinger's AcademicInfluence.com Rankings